Scarica l'app Stockscreener
15.50
10.40%
1.46
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com - Investing.com Canada
Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission - Stock Titan
Lyell Immunopharma stock maintained at Market Outperform by Citizens - Investing.com Canada
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Value Benchmark Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell Microcap Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 3000E Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL) - TradingView
LYEL Forecast — Price Target — Prediction for 2027 - TradingView
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Moomoo
LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com - Investing.com Nigeria
Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyell Immunopharma (LYEL) major holder transfers shares as commission - Stock Titan
Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone - Stock Titan
Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares - Stock Titan
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner Innovative Cellular Therapeutics Holdings Ltdmoomoo - Moomoo
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lyell Immunopharma Inc (LYEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey
Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyell Immunopharma Inc (LYEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com Nigeria
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell reports safety data for ronde-cel in lymphoma trial By Investing.com - Investing.com Canada
Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma - TradingView
New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma - Quiver Quantitative
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress - The Manila Times
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Ramachandra Sumant - Moomoo
Lyell Immunopharma (LYEL) CMO logs small tax-driven stock sale on Form 4 - Stock Titan
LYEL: All proposals passed, including director elections and auditor ratification, with no shareholder questions - TradingView
1.95%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):